Everolimus (Certican) 12-Month Safety and Efficacy Versus Mycophenolate Mofetil in de Novo Renal Transplant Recipients
- 27 November 2004
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Transplantation
- Vol. 78 (10), 1532-1540
- https://doi.org/10.1097/01.tp.0000141094.34903.54
Abstract
Everolimus is a proliferation inhibitor designed to target chronic rejection, including prevention of acute rejection. Everolimus blocks growth factor-mediated transduction signals, preventing organ rejection by a mechanism different than that of calcineurin inhibitors and of mycophenolate mofetil (MMF). Everolimus (1.5 mg or 3 mg daily) was compared with MMF (2 g daily) in a randomized, multicenter, multinational, 12-month double-blind, double-dummy and 2-year open-label, phase 3 trial in de novo renal allograft recipients (n=588) who also received cyclosporine and corticosteroids as part of a triple immunosuppressive regimen. At 12 months, there were no statistically significant differences between doses of 1.5 and 3 mg/day everolimus and MMF (2 g/day) in incidence of biopsy-proven acute rejection (23.2%, 19.7%, and 24.0%, respectively), graft loss (4.6%, 10.6%, and 9.2%), or death (5.2%, 4.0%, and 2.6%), respectively. Everolimus 1.5 mg/day and MMF were generally equally well tolerated. Both were better tolerated than everolimus 3 mg/day. The incidence of cytomegalovirus infection was significantly lower in patients receiving either 1.5 or 3 mg/day everolimus than in those receiving MMF (5.2% and 7.6% vs. 19.4%, respectively) (P=.001). Everolimus is effective in preventing acute rejection and graft loss in de novo renal allograft recipients receiving a triple immunosuppressive regimen. Prevention of acute rejection, along with reduction in cytomegalovirus infection, addresses two factors known to contribute to chronic rejection in such patients.Keywords
This publication has 21 references indexed in Scilit:
- The role of certican (everolimus, rad) in the many pathways of chronic rejectionTransplantation Proceedings, 2001
- Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporineClinical Pharmacology & Therapeutics, 2001
- Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RADBritish Journal of Clinical Pharmacology, 2000
- The use of mycophenolate mofetil in transplant recipientsImmunopharmacology, 2000
- PREVENTION OF ACUTE ALLOGRAFT REJECTION IN NONHUMAN PRIMATE LUNG TRANSPLANT RECIPIENTSTransplantation, 2000
- COADMINISTRATION OF NEORAL AND THE NOVEL RAPAMYCIN ANALOG, SDZ RAD, TO RAT LUNG ALLOGRAFT RECIPIENTSTransplantation, 1999
- Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporineThe Journal of Heart and Lung Transplantation, 1999
- SDZ RAD, A NEW RAPAMYCIN DERIVATIVETransplantation, 1997
- SDZ RAD, A NEW RAPAMYCIN DERIVATIVETransplantation, 1997
- MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN PRIMARY CADAVERIC RENAL ALLOGRAFT RECIPIENTSTransplantation, 1995